Keyphrases
Relapsed or Refractory
100%
Diffuse Large B-cell Lymphoma (DLBCL)
93%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
84%
Rituximab
80%
Lymphoma
58%
Follicular Lymphoma
57%
Overall Survival
55%
Progression-free Survival
50%
Brentuximab Vedotin
49%
Confidence Interval
47%
Mosunetuzumab
45%
Phase II Study
41%
R-CHOP
39%
Refractory Diffuse Large B-cell Lymphoma
37%
Hodgkin Lymphoma
36%
Hazard Ratio
31%
Chemotherapy
31%
Bendamustine
29%
Disease Progression
29%
Cyclophosphamide
29%
Survivorship
27%
B-cell Lymphoma
27%
Event-free Survival
26%
Etoposide
26%
Phase II Trial
25%
Prednisone
25%
Newly Diagnosed
23%
Complete Response
23%
Refractory Hodgkin Lymphoma
23%
Positron Emission Tomography
22%
Doxorubicin
21%
Non-Hodgkin Lymphoma
21%
Mantle Cell Lymphoma
21%
High-dose Chemotherapy
20%
High-dose Therapy
20%
Lymphoma Survivors
20%
Adverse Events
20%
Complete Response Rate
19%
Relapsed or Refractory Diffuse Large B-cell Lymphoma
18%
Carboplatin
18%
Previously Untreated
18%
High Risk
18%
Relapsed Lymphoma
18%
Radiation Therapy
18%
Cost of Illness
18%
Survivors
17%
Survivorship Care Plan
17%
Copanlisib
17%
Monotherapy
16%
United States
16%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
94%
Diseases
62%
Hodgkin's Lymphoma
55%
Malignant Neoplasm
53%
Rituximab
52%
Overall Survival
51%
Progression Free Survival
45%
Follicular Lymphoma
44%
Non-Hodgkin Lymphoma
41%
Mosunetuzumab
36%
B-Cell Lymphoma
32%
Radiation Therapy
31%
Stem Cell Transplant
30%
Autologous Stem Cell Transplantation
30%
Transplantation
29%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
27%
Health Care Cost
27%
Arm
25%
Drug Megadose
24%
Etoposide
24%
Adverse Event
24%
Polatuzumab Vedotin
22%
Positron Emission Tomography
22%
Mantle Cell Lymphoma
21%
High Dose Chemotherapy
18%
Cyclophosphamide
18%
Event Free Survival
17%
Brentuximab Vedotin
17%
Doxorubicin
17%
Bendamustine
17%
Carboplatin
17%
Neoplasm
16%
Disease Exacerbation
15%
B Cell
15%
Hazard Ratio
15%
Cell Transplantation
15%
Hematopoietic Cell
15%
Communication Skill
14%
Cost-Effectiveness Analysis
13%
Minimal Residual Disease
13%
Ibrutinib
13%
Polyethylene Terephthalate
13%
Cardiac Magnetic Resonance Imaging
13%
Ifosfamide
13%
Systemic Therapy
13%
B-Cell Chronic Lymphocytic Leukemia
12%
Second Cancer
12%
Cancer Therapy
12%
Copanlisib
12%
Prednisone
11%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
99%
Rituximab
83%
Follicular Lymphoma
53%
Overall Survival
51%
Progression Free Survival
45%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
41%
Mosunetuzumab
40%
Chemotherapy
37%
Diseases
35%
Cyclophosphamide
33%
Nonhodgkin Lymphoma
33%
B Cell Lymphoma
32%
Doxorubicin
28%
Polatuzumab Vedotin
27%
Prednisone
26%
Adverse Event
26%
Bendamustine
25%
Hodgkin Disease
21%
Chimeric Antigen Receptor
20%
Vincristine
18%
Etoposide
18%
Copanlisib
17%
Malignant Neoplasm
16%
Disease Exacerbation
16%
Monotherapy
16%
High Dose Chemotherapy
15%
Ibrutinib
13%
Remission
12%
Busulfan
11%
Thiotepa
11%
Carboplatin
10%
Ifosfamide
10%
Mantle Cell Lymphoma
9%
Cytarabine
9%
Maximum Tolerated Dose
9%
Bispecific Antibody
9%
Classical Hodgkin Lymphoma
9%
Cytokine Release Syndrome
9%
Hematologic Malignancy
9%
Ofatumumab
9%
Polyethylene Terephthalate
9%
Methotrexate
8%
Anthracycline
7%
Fluorouracil
7%
Placebo
7%
Lenalidomide
7%
T Cell Lymphoma
7%
Neoplasm
6%
Clinical Trial
6%
Dexamethasone
6%